Drug Trial Radar · NCT07406347
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 25, 2027
Primary completion
Oct 18, 2028
Study completion Oct 18, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 42 days, up to 90 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study
Conditions
- Pneumonia, Bacterial
Interventions
Pn-MAPS30plusBiological
Pn-MAPS30plus vaccine will be administered intramuscularly.
PCV20Combination product
PCV20 vaccine will be administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with solicited administration site adverse events (AEs)Time frame: Day 1 to Day 7
- Number of participants with solicited systemic adverse events (AEs)Time frame: Day 1 to Day 7
- Number of participants with unsolicited AEsTime frame: Day 1 to Day 30
- Number of Participants with Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to WithdrawalTime frame: Day 1 up to trial end (Month 16)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.